11,735 Shares in LivaNova PLC (NASDAQ:LIVN) Acquired by Martingale Asset Management L P

Martingale Asset Management L P bought a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 11,735 shares of the company's stock, valued at approximately $617,000.

Other institutional investors have also recently bought and sold shares of the company. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after acquiring an additional 332 shares during the period. Hexagon Capital Partners LLC grew its position in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after purchasing an additional 370 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in LivaNova in the 1st quarter worth $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova in the 2nd quarter worth $88,000. Finally, Central Pacific Bank Trust Division acquired a new stake in LivaNova in the 3rd quarter worth $178,000. Institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $0.67 during trading on Tuesday, reaching $51.62. The company had a trading volume of 410,662 shares, compared to its average volume of 609,249. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The stock has a market cap of $2.80 billion, a PE ratio of 122.90 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The business's 50 day moving average price is $52.29 and its 200-day moving average price is $52.03.

Analysts Set New Price Targets

LIVN has been the topic of several recent research reports. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They set a "buy" rating and a $65.00 target price on the stock. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, October 31st. Finally, Needham & Company LLC restated a "buy" rating and issued a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.